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Abstract: Diabetes is a complex disease characterized by hyperglycemia, together with polyuria,
polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic,
environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the
organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral
insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the
animal model should be carefully selected among the wide variety of the currently available ones.
This review discusses the most common animal models currently employed to study T1DM and
T2DM. Moreover, an overview on the administration routes that could be used is also discussed.
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1. Introduction
Diabetes mellitus (DM) is one of the current leading health problems worldwide. DM comprises
a group of metabolic diseases characterized by hyperglycemia, as insulin production by pancreatic
β-cells is either insufficient or even absent, and target cells do not respond to circulating insulin [1,2].
Associated with hyperglycemia, together with common symptoms, namely polyuria, polydipsia, and
polyphagia [1], DM is a silently life-threatening condition that may culminate on hemodynamic and
cardiovascular complications, metabolic complications, and altered genetic susceptibility [3]. Also,
long-term developing diseases, as a consequence of hyperglycemia affecting the whole organism or
being organ specific, as is the case of diabetic retinopathy, is in the natural course of the disease [4].
DM is classified into two main types: type 1 DM (T1DM), previously known an insulin dependent
DM (IDDM), and type 2 DM (T2DM), previously known as non-insulin dependent DM (NIDDM) [5].
In addition, gestational DM is characterized by the development of DM by pregnant women with
hyperglycemia during pregnancy with no previous history of the disease [3]. T1DM results from a
complex disease process in which genetic, environmental factors, and/or immune dysfunction lead
to an autoimmune response, resulting in pancreatic β-cell destruction, depriving the organism from
endogenous insulin [6,7]. T2DM comprises about 85% of DM cases and is characterized by peripheral
insulin resistance. Compensatory insulin hypersecretion from pancreatic β -cells precedes the decline
in islet secretory function. Reduced insulin sensitivity affects mainly the skeletal muscle, liver, and
adipose tissue, as these tissues have particular requirements for glucose uptake and metabolism [3,7].
In general, DM consequences affect various systems, organs, and tissues [4,8–11], being therefore
difficult to predict in the exact consequences of the disease, as genetic, nutrition, environment, and
other factors are different in each individual [10,11]. With these constraints, several animal models
have been developed, aiming at assessing the causes and consequences of DM, in order to achieve
effective and safe treatments. This review describes the animal models currently available to study
DM and its complications. Additionally, since the administration routes are of crucial relevance in
order to study their effectivity, a comprehensive overview about the different administration routes
used for pre-clinical and clinical trials has been undertaken. In this sense, the key to successful drug
development relies on the suitable selection of the animal model and the drug administration route.
2. Diabetes Mellitus Animal Models
The study of DM comprises the study of normal individuals, as only by knowing how a
physiological organ/tissue responds to stimuli can we correlate to the altered response in compromised
organ/tissues. The study of glucose regulated insulin secretion, as well as its modulation by oral
antidiabetic-drugs, has been made with resource to albino mice (Charles Rivers breeding), using
isolated islets of Langerhans [12,13] or isolated pancreatic β-cells [14,15]. Other sources of pancreatic
β-cells from physiological donors have also been used, such as porcine, human, canine, among
others [13–15].
Animal models may be developed by two principal mechanisms: disease induction (e.g., using
specific drugs) or genetic manipulation. Both are of extreme relevance as they allow the study of
specific disease-related mechanisms and are essential to understand the pathogenesis and progression
of the diseases and extrapolate to humans.
Since T1DM and T2DM are metabolic disorders, representing complex integrating bodily systems,
choosing the adequate animal model to use in specific in vivo experiments requires careful consideration [16].
To attain this objective, a careful analysis must be performed when choosing a DM animal model, regarding
particular aspects of the disease and the specific knowledge that is aimed in each study [16]. In this context,
T1DM animal models include spontaneously developing autoimmune diabetic animals, or animals that
have been subjected to chemical ablation of pancreatic β-cells. On the other hand, T2DM animal models
are more numerous, and may embrace obese and non-obese models, with variable insulin resistance and
β-cell failure degrees [16]. In addition, transgenic and knock-out mouse models are also available, but their
use in the research field is still controversial, as it will be herein focused [16].
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Table 1. Animal models most commonly used to study type 1 diabetes mellitus.
Induction Mechanism Model Main Features Possible Uses Advantages Disadvantages Ref.
Chemical induction
High single-dose
streptozotocin (STZ) *
Simple model of
hyperglycemia
Testing drugs (new insulin
formulations) or therapies
(transplantation)
• A more stable model • Mortality is relatively
more frequent
[17,18]
• Comparatively cheaper, easier to
develop and maintain
Multiple low dose
streptozotocin (STZ) * Model of induced insulitis
Treatments that may prevent
β-cell death
• Used for longer
experimental studies
• May produce toxic effects on
other tissues
• May be applied to higher animals
• STZ is relatively unstable and
solution should ideally be made
immediately prior to injection
Alloxan *
Simple model of
hyperglycemia
Transplantation models
• Selective loss of pancreatic β-cells
leaving α and δ cells intact
• Hyperglycemia develops
primarily by direct cytotoxic
action on the β-cells and insulin
deficiency rather than
consequence of insulin resistance
[19,20]• Animals live longer without
insulin treatment (since there is a
residual insulin secretion)
• Less stable and reversible
because of the spontaneous
regeneration of β-cells
• Relatively less ketosis and
resulting mortality
• May produce toxic effects on
other tissues
• Comparatively cheaper, easier to
develop and to maintain
• High variability of results on
development of hyperglycemia
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Table 1. Cont.
Induction
Mechanism Model Main Features Possible Uses Advantages Disadvantages Ref.
Spontaneous
autoimmune
Non-obese diabetic (NOD)
mice (Spontaneous autoimmune
model of choice)
β-cell destruction due to an
autoimmune process
Understanding genetics of
T1DM
• Hyperlipidemia can be also
studied, as lipid content increase
• Polyphagia and
polyuria occurrence [16,21,22]
Biobreeding (BB) rats Understanding mechanism ofT1DM • Hyperglycemia persists for
several days
• A diabetes and obesity
symptom overlaps
[23,24]
LEW.1AR1/-iidm rats
Treatments that may prevent
β-cell death and/or manipulate
autoimmune process
• Not identical to those in
human disease
Genetically induced AKITA mice * β-cell destruction due to ERstress. Insulin dependent.
New formulations of insulin
Transplantation models
Treatments to prevent ER stress
• The lack of β-cell mass makes it
an alternative to STZ-treated
mice in transplantation studies
[25,26]
Virally-induced
Coxsackie B virus
β-cell destruction induced by
viral infection of b-cells
Establish potential role of
viruses in the development of
T1DM
• Stable and irreversible diabetes
can be induced
• Comparatively costlier
to develop
[27]
Encephalomyocarditis virus
Kilham rat virus
LCMV under insulin
promoter • Technical expert is required to
handle of virus
Non-rodent models
Pancreatectomy
Hyperglycemia induction in
pigs, dogs and primates
Treatments that may prevent
β-cell death
Transplantation models
• Reasonably accurate model of
auto transplantation of islets
in humans
• Very invasive surgery
[28]• In large animal models,
spontaneous diabetes is relatively
rare and unpredictable in onset
Chemical ablation of β-cells
in large animals • Some models combine a partial
pancre-atectomy with STZ
treatment, thus reducing the dose
of STZ
• Interspecies variation in the
β-cell toxicity of alloxan or STZ [28]
• Narrow window of efficacy.
* Also used in T2DM research.
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Table 2. Animal models most commonly used to study type 2 diabetes mellitus.
Induction Mechanism Model Main Features Possible Uses Advantages Disadvantages Ref.
Obese monogenic
models
Lepob/ob mice (mutated leptin
gene)
Obesity-induced
hyperglycemia, with
hyperphagic, obese,
hyperinsulinaemic and
hyperglycemic animals
Treatments to improve insulin
resistance
• Pancreatic islet volume
dramatically increased
• Infertile mice
[29]
• Metabolic aberrations
(hyperlipidemia disturbance in
temperature regulation, lower
physical activity)
• Diabetes not particular severe
and thus not completely
representative of human T2DM
Leprdb/db mice (mutated
leptin receptor gene) Treatments to improve β-cell
function
• Ketosis after a few months of age,
having a relative short lifespan [30]
Zucker Diabetic Fatty (ZDF)
Rats (mutated leptin receptor
gene)
• Diabetic complications
also develop
• Hypertensive rats
[31]
• Females do not develop
overt diabetes
Obese polygenic models
KK mice
Obesity-induced
hyperglycemia
Treatments to improve insulin
resistance
Otsuka Long-Evans
Tokushima Fat (OLEFT) rat
Treatments to improve β-cell
function
• Three stages of histological
changes can be observed [32,33]
New Zealand Obese (NZO)
mice
Some models show diabetic
complications
• Renal complications
TallyHo/Jng mice
• Adiposity, plasma triglycerides,
cholesterol and free fatty acid
levels are increased • Only male mice
develop hyperglycemia
NoncNZO10/LtJ mice
• Indicated for diabetic wound
healing studies
• Nephropathy presence
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Table 2. Cont.
Induction
Mechanism Model Main Features Possible Uses Advantages Disadvantages Ref.
Induced obesity
models
High fat feeding (mice or rats)
Obesity-induced
hyperglycemia
Treatments to improve insulin
resistance
• Baboons and humans are
genetically, anatomically and
physiologically very similar
• Handling of baboon is
somewhat difficult
[31,33]
Desert gerbil Treatments to improve β-cellfunction • Cardiac complications can
be studied
• Veterinarian is required
Nile grass rat Treatments to preventdiet-induced obesity
• Costly model containing
Non-obese models Goto-Kakizaki (GK) rat
Hyperglycemia induced by
insufficient β-cell function or
mass
Treatments to improve β-cell
function • Allow the study of β-cell function
and diabetic complications
• Interstrains variability of the
islets morphology
and metabolism
[31,33]
Treatments to improve β-cell
survival
Genetically induced
models of β-cell
dysfunction Human islet amyloid
polypeptide-expressing
(hIAPP) mice
Amyloid deposition in islets
Treatments to prevent amyloid
deposition • Express human IAPP under the
insulin promoter, which can form
amyloid within the islets for
further study
• Transgenic mice [31,33]
Treatments to improve β-cell
function
β-cell destruction due to ER
stress
Treatments to prevent ER stress • β-cell adaption to increased
insulin demand is restrictedTreatments to improve β-cell
survival
Non-rodent models
Cat models
Amyloid deposition in islets Treatments to improve β-cellfunction • Islet amyloidosis study • More expensive models
[31,33–37]β-cell destruction Treatments to preventdiet-induced obesity
Old-world non-human
primates
• Similarities to human condition
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The models most commonly used to study T1DM and T2DM are summarized in Tables 1 and 2,
respectively, together with their main advantages and disadvantages. In an idealistic perspective and
aiming a reliable representation of the diversity observed among diabetic human patients, at least two
or more animal models should be employed, taking into account the principles of the four Rs, i.e.,
replacement (preference for methods that avoid or replace animals use), reduction (use methods which
minimize the number of animals per experiment), refinement (prefer methods regarding a minimal
animal suffering and that promote their welfare), and responsibility [16].
3. Diabetes Mellitus Type 1 Animal Models
T1DM is mainly characterized by pancreatic β-cells autoimmune destruction, which contributes
to insufficient insulin production, or even to the absence of insulin secretion [16]. In animal models of
T1DM, this deficiency may be reproduced by several mechanisms, ranging from β-cells destruction
either by chemical ablation using normal animal models to breeding animals (mostly rodents) that
suffer from spontaneously developed autoimmune diabetes [16,38,39]. Some of the most commonly
used models of T1DM are outlined in Table 1 and are mainly constituted by rodent models, but some
higher animals, such as pigs, dogs, and primates, have also been used (Table 1).
3.1. Chemical Induction of Diabetes Mellitus Type 1
3.1.1. Streptozotocin (STZ)-Induced Models
Streptozotocin (STZ), chemically known as N-(methylnitrosocarbamoyl)-α-d-glucosamine, is a
naturally occurring compound produced by Streptomycetes achromogenes with antibiotic properties
that are selectively taken up by pancreatic β-cells, causing its destruction [16,40]. After its intraperitoneal
or intravenous administration, STZ behaves as a glucose analogue and is transported mainly by the
glucose transporter subtype 2 (GLUT-2) [41] into the pancreatic β-cell, where it induces toxicity, mainly
by producing DNA alkylation [16]. Due to DNA strand breaks, over-activation of poly-ADP ribose
polymerase (PARP) leads to NAD+ depletion, cellular ATP reduction, and consequently, insulin production
is compromised, as well as the cell survival, since there is a massive loss of energy [42]. As STZ enters the
cell via GLUT-2, this is also expressed in other cells behind those from the pancreas, as the toxic action
of STZ is not specific to pancreatic β cells, occurring also in hepatocytes and kidney cells (Figure 1) [43].
These are probably the reasons underlying the high mortality rate associated with this model.
Figure 1. Streptozocin diabetes induction model (based on [17]). (A) Single-dose Streptozocin, (B)
Multiple-low dose streptozocin, (C) Streptozocin mechanism on the β-cells nucleus and side effects in
other organs with glucose transporter subtype 2 (GLUT-2) receptors. Streptozotocin (STZ) behaves as a
glucose analogue and is transported into the pancreatic β-cell by GLUT-2. It produced DNA alkylation and
over-activation of poly-ADP ribose polymerase (PARP) causing NAD+ depletion, cellular ATP reduction,
and compromising insulin.
J. Clin. Med. 2019, 8, 1332 8 of 20
Depending on the severity of the intended model disease, STZ-induced DM models usually result
from one of the following procedures: administration of a single high STZ dose, or as multiple low
STZ doses [16]. In the high-dose STZ administration procedure, a single STZ dose is administered to
mice (100–200 mg·kg−1) or rats (35–65 mg·kg−1) by intravenous or intra-peritoneal routes, producing
massive pancreatic β-cell destruction with little or no insulin production [43]. Insulinemia must be
recorded to ensure that the intended model is stable, since there is some evidence that pancreatic
islets regeneration may occur after this single-dose treatment. On the other hand, multiple low-dose
STZ administration implies that small doses (20 to 40 mg·kg−1·day−1) are to be administered over
a period of time in order to promote insulitis [16,18]. During insulitis development, infiltration of
macrophages in the pancreatic islet promote cytokine production-dependent T1DM development.
Therefore, therapies which target cytokines and nitric oxide are highly probable to be successful in
reducing diabetes development in this model.
Both STZ-induced diabetes models are cheaper and easier to perform than the remaining models
and they can be used in most strains of rodents, or other animals, opening the field of diabetes research
to an array of genotypic and phenotypic options that would otherwise be inaccessible [18,43].
3.1.2. Alloxan-Induced Models
Alloxan (2,4,5,6(1H,3H)-pyrimidinetetrone, 2,4,5,6-tetraoxypyrimidine,5,6-dioxyuracil) is also
used to chemically induce DM and two possible mechanisms have been proposed. One suggests that
alloxan selectively inhibits glucose-induced insulin secretion through specific inhibition of glucokinase,
the pancreatic beta cell glucose sensor [44], and it also induces reactive oxygen species (ROS) formation,
creating a redox cycle generating superoxide radicals. Alloxan is reduced to dialuric acid and then
re-oxidized back to alloxan, producing superoxide radicals that undergo dismutation (by superoxide
dismutase) to form hydrogen peroxide; concomitantly, hydroxyl radicals may also be formed by side
reactions. These highly reactive oxygen species may cause β-cell DNA fragmentation, leading to
apoptosis [16,44,45]. Although alloxan is also taken up by the liver, hepatotoxicity induced by alloxan is
minimal or null since the liver has more effective protection mechanisms against ROS than β-cells [45],
and they also have several mechanisms for xenobiotic biotransformations and elimination. Alloxan
also promotes the essential –SH groups oxidation, especially that of gluthatione (GSH), enzymes,
and proteins, and also dysregulates intracellular calcium homeostasis, leading to supraphysiological
calcium concentrations and, hence, cellular damage [16,44,45].
Alloxan administered doses range from 50 to 200 mg/kg (in mice) and 40 to 200 mg/kg (in rats),
and they are dependent on the chosen strain and the route of administration (e.g., intraperitoneal
and subcutaneous alloxan administration require doses up to three times of those administered by
intravenous route) [16]. Alloxan induces DM models as a consequence of ROS mediated beta cell
toxicity (Figure 2), allowing the investigation and understanding of ROS mediated mechanisms of beta
cell death in both T1DM and T2DM [44].
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Figure 2. Alloxan induced diabetes mechanism (based on [46]). Alloxan is reduced to dialuric acid and
re-oxidized to alloxan producing alloxan radicals and reactive oxygen species (ROS) which undergo
dismutation (by superoxide dismutase, SOD) to form hydrogen peroxide (H2O2). Hydroxyl radicals
(*OH) may also be formed by side reactions. These *OH cause β-cell DNA fragmentation, leading
to apoptosis.
3.2. Spontaneous or Autoimmune of Diabetes Mellitus Type 1
3.2.1. Non-Obese Diabetic Mice
The non-obese diabetic (NOD) mouse model originated in the inbreeding of the Cataract Shionogi
(CTS) strain in the 1980s. The NOD mouse model is an autoimmune disease model where the T1DM
develops spontaneously [21]. NOD mice exhibit polyuria, glycosuria, weight loss, and lymphocytic
infiltration of the islets of Langerhans within the pancreas. It has been observed in NOD mice that
innate immune cells infiltrate the pancreas of NOD mice at 3 weeks of age. In the same way, these
cells types, such as dendritic cells, macrophages, and neutrophils, are also found in the human islet
infiltrate [47]. The infiltration of innate immune cells into the islets attract adaptive CD4 and CD8 T
cell subsets, which are required for DM development, into the islets from approximately 4 to 6 weeks
of age [21,46].
Additionally, the relevance of this model relays in the fact that it was able to identify key genetic
and environmental risk factors, such as effects of microorganisms including the gut microbiota, and
how they may contribute to T1DM [21].
3.2.2. Biobreeding Rats
The biobreeding (BB) rat model was developed in the 1970s from outbred Wistar rats [21]. The
incidence of diabetes is the same in male and female BB rats, although in humans it is reported to have
a slight prevalence in males [23]. The BB rats develop T cell-specific lymphopenia and an impairment
of Treg cell function. At 5 weeks, the BB rats develop insulitis, followed by hyperglycemia in around
70% of the animals [23]. Once hyperglycemia occurs, BB rats manifest polyuria, leading to a severe loss
of body weight despite excessive drinking. Afterwards, these rats will develop ketoacidosis within
several days [23]. According to Medina and colleagues, in this model there is a deterioration of beta
cell function and mass as well as intra-islet blood flow that precedes insulitis and diabetes [24]. These
underlying changes in islet function may be previously unrecognized factors of importance in type 1
diabetes development [24].
3.2.3. LEW.1AR1/-Iddm Rats
The LEW.1AR1-iddm rat is an animal model T1DM, which arose through a spontaneous mutation
in the Dock8 gene within the major histocompatibility complex (MHC) congenic background strain
LEW.1AR1 [48]. This Dock8 mutation provides a deepened insight into the impact of genes involved
in diabetes development [48]. The mutation leads to a variable T-cell frequency in peripheral blood.
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The secondary lymphatic organs, such as lymph nodes and spleen, show 15% less T cell frequency,
whereas the frequency of β-cells increased by 10% in the lymph nodes and by 5% in the spleen [49].
According to Arnd and colleagues, the Dock8 mutation is responsible for changed immune cell
frequencies in different compartments, together with the RT1B/Du haplotype autoimmune diabetes [49].
3.3. Genetically Induced Diabetes Mellitus Type 1
AKITA Mice
One of the most widely used genetically induced diabetic mouse models is AKITA mice. These
mice possess a mutation in Ins2, causing abnormal folding of insulin [48,49]. This model involves
chronic stress on protein processing, involving the endoplasmic reticulum and unfolded protein
response, triggering apoptosis and diabetes. The unfolded protein response tries to compensate and
reduces the protein load of the endoplasmic reticulum, increasing its folding capacity [50]. This leads
to toxicity in pancreatic β cells, decreasing their insulin secretion. Hyperglycemia is found in males,
but it is attenuated in female mice [49]. In comparison with STZ induction, AKITA mice develop more
robust alterations in albuminuria and kidney structure [49].
3.4. Virally Induced Diabetes Mellitus Type 1
Viruses have been observed as a factor that could be implicated in the pathogenesis of DM1 [51].
In this sense, different viruses are able to induce T1DM, such as Coxsakie virus, encephalomyocaridits
virus, Kilham rat virus, lymphocytic choriomeningitis virus rubella, and mumps (see Table 1). These
viruses stimulate autoreactive T cells that participate in islet destruction by triggering β-cell-specific
autoimmunity that end up in destruction of the β-cells [51].
3.5. Non-Rodent Models of Diabetes Mellitus Type 1
3.5.1. Pancreatomy
Pancreatomy is a reliable but invasive method to induce hyperglycemia and has been used in pigs
and primates [16]. However, this method leads to pancreatic exocrine deficiency in the animal [16].
Moreover, partial pancreatomy can be combined with STZ treatment [16].
3.5.2. Chemical Ablation of β-Cells in Large Animals
Chemical ablation of beta cells in large animals could be undertaken using STP or alloxan, as
previously explained. However, it has the main drawback of interspecies variation requiring different
dosages, which can cause variated effects [16].
4. Diabetes Mellitus Type 2 Animal Models
Briefly, T2DM is mainly characterized by hyperglycemia due to insulin resistance and pancreatic
β-cell insufficient compensating, leading to metabolic impairments for several organs and tissues,
namely, adipose and muscular tissues. To study the onset, progress, and effective treatments for T2DM
complications, several animal models have been established in order to investigate the mechanisms
and pathophysiology of T2DM. Thus, these animal models may include models of insulin resistance or
β-cell failure, but also models that develop diseases related to hyperglycemia exposure. Animal models
of T2DM can be divided into artificially induced diabetic models, spontaneously diabetic models, and
transgenic/knock-out diabetic models. Independently of the T2DM animal model type, the majority of
the animals are obese, with several degrees of obesity, modeling, hence the close association of obesity
and T2DM development, similar to the metabolic syndrome [16,52].
In this respect, obese models can be monogenic or polygenic. Most monogenic models have a
defect in the signaling of leptin, which is the key regulator of energy balance, body adiposity, and
glucose homeostasis. Leptin signaling was shown to be compromised in metabolic diseases, such
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as obesity and diabetes mellitus, corroborating the relevant role of this hormone in the etiology and
pathophysiological manifestations of those conditions [52]. Some monogenic animal models with
compromised leptin signaling are described in Table 2.
Polygenic models of obesity provide a more reliable model of the human condition, and, therefore,
efforts have been made to construct models in which several genes have been altered or even deleted.
Thus, a great variety of these models have been employed to study obesity, glucose intolerance,
and DM, since they also allow a great variety of genotypes to be assessed [16,53,54]. These models
have been used to study the correlation between obesity and insulin resistance, to study the possible
reversion of T2DM symptoms, to correlate obesity and glucose homeostasis, aiming, in general, a
better understanding of T2DM and associated complications.
Some of the most commonly used models of T2DM are described in Tables 1 and 2, as some
models can be used to treat both types of DM. In particular, some additional considerations about KK
mice (obese polygenic model) and high-fat feeding models will be mentioned next.
4.1. Obese Monogenic Models of Diabetes Mellitus Type 2
Genetic manipulation can also identify genes of interest in the development of diabetes. Monogenic
models are useful in understanding the connection between how insulin resistance develops in an
obese phenotype [55]. In this sense, the most common models are discussed below.
4.1.1. Lepob/ob Mice
The Lepob/ob mice were deficient in leptin, leading to an increased body weight and
hyperinsulinaemia [55]. Hyperglycemia appears at 4 weeks of age and increases until around 4
months. Islet mass is increased, and insulin secretion is maintained in this model in addition to reduced
metabolic rate, dysregulation of thermogenesis, hyperlipidemia, and infertility [55].
4.1.2. Leprdb/db Mice
These mice have an autosomal recessive mutation in the Ob-Rb leptin receptor [55]. These animals
present hyperphagia, obesity, hyperinsulinemia, and hyperglycemia. Interestingly, the background
mice possess a strong effect on the severity of the phenotype, e.g., on a C57Bl/KSJ, where the animals
develop severe ketogenesis and have a short life span, whereas on C57BL/6 mice, these symptoms are
considerably milder [55].
4.1.3. Zucker Diabetic Fatty (ZDF) Rats
The Zucker fatty rats were discovered from the simple autosomal recessive (fa) gene on
chromosome after a cross of Merck M-strain and Sherman rats in 1961 as a model for human
obesity and T2D [51]. These rats possess a hypothalamic defect in leptin receptor signaling, which
is associated with type IV hyperlipidemia and hypertension. These rats develop proteinuria and
glomerulosclerosis, ultimately leading to renal failure [51]. In some cases, abnormal glucose tolerance
is also reported, due to the metabolic defects in the hepatic organ [51].
4.2. Obese Polygenic Models of Diabetes Mellitus Type 2
There are a variety of different polygenic models of obesity. These may more accurately reflect
human disease, which is generally polygenic. However, one disadvantage of these models is that they
have no wild-type control [56].
4.2.1. KK Mice Models
KK mice strain derives from wild-derived ddY mice, which are obese and hyperleptinemic. This
model develops severe hyperinsulinemia and insulin resistance (in both muscle and adipose tissue).
Total pancreatic insulin content is increased, leading to hypertrophic and degranulated pancreatic
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islets. This strain also develops diabetic nephropathy signs, increased glucose, and hemoglobin HbA1c
levels, and impaired glucose tolerance [16,57]. As several breeding colonies of these mice have been
maintained in several laboratories, there are now several substrains, such as T-KK (or Toronto-KK,
KK/Upj), KK/HlLt, KK/Ta, and KK/San [57]. A substrain of the KK model, the KK-AY mice, was created
by inserting a yellow obese AY gene (mice develop yellow coat instead of dark), an introgression of the
AY mutation in an agouti gene. This strain develops maturity-obesity, more severe hyperinsulinemia,
and more prominent pancreatic islets alterations, mainly due to the ectopic expression of the agouti
protein which functions as a melanocortin receptor 4 (MCR4) antagonist in the hypothalamus, which
has increased HbA1c and exhibits early stage nephropathy [16,57,58].
4.2.2. Otsuka Long-Evans Tokushima Fat (OLEFT) Rat
The Otsuka Long-Evans Tokushima Fat (OLEFT) rat was derived from a spontaneous obesity in
an outbred colony of Long Evans rats in the 1990s [59]. These rats show a deficit in the cholecystokinin
(CCK)-1 receptor gene, resulting in the absence of CCK-1 receptors in the gastrointestinal track and the
brain. OLETF rats have increased expression of hypothalamic neuropeptide Y (NPY), thus contributing
to the hyperphagia developed by these animals. The study of OLETF rats has roles of the NPY in
energy balance and glucose homeostasis [59].
4.2.3. New Zealand Obese (NZO) Mice
New Zealand obese (NZO) mice is a model of obese mice due to hyperphagia and reduced
expense of energy [32]. NZO mice develop insulin resistance, hypertension, and hypercholesterolemia.
Hyperglycemia and hyperinsulinemia are also found at early ages, and they are associated with β-cell
destruction [32]. Gender differences have been observed in this model, with males presenting increased
rates of T2DM [32].
4.2.4. TallyHo/Jng Mice
TallyHo mice were developed by Jackson laboratory from the progeny of diabetic males [60].
Obesity and reduced insulin sensitivity may be key features for diabetes in Tally-Ho mice [60].
They develop hyperglycemia between 10 and 14 weeks of age. Also, they show hyperinsulinemia,
hyperlipidemia, moderate obesity, and enlargement of the islets of Langerhans [60].
There are marketed gender differences, since females do not show DM, despite displaying
moderate hyperinsulinemia, hyperlipidemia, and obesity [60].
4.2.5. NoncNZO10/LtJ Mice
NoncNZO10/LtJ mice were generated by combining New Zealand obese (NZO/HlLt) mice and
non-obese non-diabetic (NON/ShiLtJ) mice at the Jackson laboratory [61]. NoncNZO10/LtJ mice are
not hyperphagic and do not show hypercorticism, and no thermoregulatory defects [62]. At 8 weeks,
male mice develop insulin resistance and increased hepatic glucose production that leads to obesity
and T2DM at around 13 weeks of age [62]. These animals show early islet hypertrophy, followed by
β-cell degradation and β-cell atrophy [62].
4.3. Induced Obesity Models of Diabetes Mellitus Type 2
4.3.1. High Fat Feeding Models
It is known that high fat feeding contributes to the development of obesity, hyperinsulinemia,
and glucose homeostasis impairment, since there is insufficient compensatory action by pancreatic
islets, resulting in impaired glucose tolerance and weight gain [63]. To create this model, the normal
diet (consisting of about 26% protein, 63% carbohydrate, and 11% fat) given to C57BL/6J mice was
replaced by a diet in which the number of calories from fat is substantially increased, contributing
to around 58% of total calories daily consumed [63]. During the establishment of this model, a strict
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monitoring of the daily eaten food is essential, in order to ensure that mice are not eating less than
usual [16]. This model developed several characteristics of human T2DM symptoms—hyperglycemia,
hyper-insulinemia—followed by a decline in insulin secretion and weight gain [63]. Ultimately, some
attention should be paid to the strain’s background when attempting to induce a model of T2DM, as it
may determine the susceptibility of intended metabolic alterations induced by diet.
4.3.2. Dessert Gerbil
Diabetes in Dessert gerbil rats (Psammomys obesus) was discovered by chance observation in
desert rodents collected by the US naval medical research unit in Egypt in the 1960s [64]. They are
characterized by muscle insulin resistance and the incapacity of insulin to activate insulin signaling on
a high energy diet. This leads to hyperglycemia and hyperinsulinemia, resulting in beta cell failure
and increased proinsulin secretion [64]. On a high energy diet, the animals did not persist for more
than a few months [65].
4.3.3. Nile Grass Rats
The Nile grass rat (NGR), Arvicanthis niloticus, is an herbivorous African murine rodent [66]. Fed
a conventional lab diet, NGRs spontaneously develop obesity, hyperglycemia, and hypertension [66].
However, these rats do not develop diabetes in the wild, but it is induced under laboratory
conditions [67]. The disease is manifested in various organs, such as lipid deposition in the liver,
advanced glycation end product (AGE) deposits in the kidney, and beta-cell failure [67].
Since there are a wide range of animal models available in order to study DM, a careful choice of
the animal models pretended for experimental use should be performed, attending to the exact purpose
of the study. Thus, aiming at developing successfully experiments using the least possible number
of animals, the choice of an animal model for DM study should respond to the initial investigational
question. If T1DM is the target of the study, the required autoimmunity and the timing and predictability
of onset (variable among strains) must be considered, as well as the islet cell destruction mechanisms.
For T2DM, the mechanisms underlying hyperglycemia, in non-obese and in obese models, such as the
associated pathologies (e.g., atherosclerosis, dyslipidemia) and other complications, namely diabetic
nephropathy and neuropathy, must be taken into account. Furthermore, subjects’ gender, genetic
phenotype, and environmental background are also relevant to the study.
In addition to the animal model, in order to obtain robust and reproducible results, a suitable drug
administration should be performed. The route has to take into account the drug’s physicochemical
parameters, sample volume, animal safety, and also be able to extrapolate results into the clinical practice.
Administration of substances to the different diabetic animal models requires careful consideration
and planning to optimize delivery of the agent to the animal, while minimizing potential adverse
experiences from the procedure.
5. Administration Routes
When preparing a pharmacokinetic experiment using laboratory animals, together with the
preparation of the animal before drug administration (feeding versus fasting), the appropriate
administration route, site of administration, and sample volume should be adequately set. The
administration routes that require less manipulation techniques are recommended [68]. In animal
experimentation, several routes for substance administration are currently available, namely enteral
(through the digestive tract), either oral (into the mouth) or gavage (esophageal, gastric, nasogastric
or orogastric), intravenous (into a blood vessel), epicutaneous (onto the skin), intradermal (into the
skin), subcutaneous (under the skin), transdermal (across the skin), intramuscular (into a muscle),
transcorneal (onto the eye), intraocular (into the eye), intracerebral (into the brain), epidural (into the
dura mater surrounding space), intrathecal (into distal spinal cord surrounding space), intraperitoneal
(into the peritoneal cavity), intraosseous (into the marrow cavity), intranasal (sprayed into the nose and
then absorbed by the nasal mucous membranes or into the lungs), intratracheal (into the lungs by direct
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tracheal instillation), inhalation, and other less common techniques, such as those using other body
natural orifices, surgical exposure, and others regarding species-specific anatomic features [68–72].
5.1. Enteral Administration
The enteral administration route comprises techniques in which the substance is delivered
through the digestive tract, such as addition of drugs to drinking water, to the food, intragastric
administration through oral gavage or rectal administration [68,73,74]. This route is very economical,
practical, and considered as safe, depending on the compound being tested. However, it presents some
limitations: (i) slower onset of action, (ii) potentially significant first-pass effect by intestine and liver,
(iii) lack of systemic absorption from the digestive tract, (iv) poor efficacy, (v) poor compliance when
voluntary administered, and (vi) the impossibility of using the procedure in unconscious subjects
or in individuals with clinically relevant diarrhea or emesis. Special concerns must be taken when
administering a large volume administration by orogastric or nasogastric gavage, since it may lead to
stress by promoting gastric distension in species that cannot vomit (e.g., rodents); smaller volumes
(~5 mL/kg) are preferable [68]. This administration route is mainly preferable for single administrations
or short-period administrations, as longer administrations may lead to animal stress or discomfort.
When animals avoid food or beverage because of a drug’s flavor or smell, administration may be
done using oral gavage [73,74]. This route opens a window in order to aid the development of enteral
nutrition formulas, such as the recent study published by Mesejo and colleagues which developed a
high-protein diabetes-specific formula that reduces insulin needs and improves glycemic control [75].
Moreover, nutraceuticals can also be explored as a new strategy in order to treat diabetes.
5.2. Intravenous Administration
This route is quite efficient and advantageous, since drugs do not suffer the first-pass-effect by
the liver, and bioavailability is 100% [68]. This route is convenient when: (i) a rapid drug effect is
required, (ii) continuous administration (infusion) is intended, (iii) large volume dosage drug is needed;
and (iv) other routes provides are not appropriate [68,73]. The choice of administration site depends
greatly on the animal, such as the jugular vein in the neck (e.g., large animals, rats) and tail vein (e.g.,
mice, rats) [53]. Special attention should be paid to drugs pharmacokinetics, individual maximum
tolerated dose, dosing intensity, and minimal variation in peak and blood concentrations required.
The procedure requires aseptic preparation of the skin for percutaneous venous injection, ensuring
that the substance is sterile and aseptically delivered [68,76]. A long-term intravenous administration
should be closely monitored to avoid, specially, pulmonary edema [68,73,76]. On the clinical practice,
this route is applied for emergencies, such as Diabetic ketoacidosis, hyperglycemic hyperosmolar state,
and hypoglycemia, which are serious complications of diabetes mellitus [77].
5.3. Intraosseous Administration
Intraosseous administration is mainly used for crystalloid fluids delivery, as an alternative to the
intravenous route in hypovolemic individuals (whose veins are inaccessible or collapsed) and also in
human pediatric medicine [78]. The medullary cavity veins allow the substance to enter directly into
the blood flow, although it is difficult to perform and is potentially invasive, and animals are usually
anesthetized [68,78]. This route is rarely used for diabetes preclinical or clinical studies.
5.4. Dermal Administration
The administration of drugs using the skin rout may be divided into: (i) topical application,
i.e., drugs are intended to treat local skin infections (e.g., genital mucosas [79]), burns, inflammation,
and wounds, and drugs are absorbed across the epidermis through paracellular and transcellular
mechanisms, but drug concentration in the blood is negligible; (ii) transdermal application, in which
drugs are applied and absorbed through the skin or mucosal membranes instead of by oral or injectable
routes, they are intended to treat areas of the body away from the site of application (e.g., hormone
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replacement therapy using patches); (iii) intradermal application (drug is deposit into the dermis using
a needle, usually forming a bubble) and; (iv) subcutaneous administration (drug is injected in between
the skin and muscle) are convenient routes to insulin administration (e.g., [80]). With drug delivery
through the skin, in animal models, one must keep in mind the following important factors: surface
area, substance concentration, lipid solubility, skin contiguity, skin thickness (at the application site),
contact duration, skin hydration, surface occlusion, and overlying hair [48]. Reports obtained using
this route focus on the improvement of wound healing of diabetic patients [81,82].
5.5. Muscle Administration
Intra-muscular administration comprises a parenteral route commonly used for large animals and
humans, since they have a great muscle mass. The rich muscle vascular supply allows a homogeneous
and rapid substance absorption, when compared to subcutaneous route, where smaller substance
volumes are administered and a more complex technique is required [68]. Some considerations to keep
in mind are: avoidance of irritating compounds or accidental nerve injection, which may lead to paresis,
paralysis, localized muscle fiber destruction, and even necrosis [83,84]. New therapies are recently
being explored using this route, such as the intramuscular administration of human placenta-derived
mesenchymal stromal-like cells for patients who have a diabetic foot ulcer with peripheral arterial
disease [85].
5.6. Epidural and Intrathecal Administration
When a prompt effect on cerebrospinal tissues or meninges is desired, testing substances may be
administered either into the epidural or subarachnoid (also named intrathecal) spaces of the spinal
cord, thus avoiding the usual absorption restrictions of the blood–brain barrier (BBB) [68]. It is
commonly used to induce spinal anesthesia and to visualize vertebral bodies, for example, in contrast
imaging studies. It requires an aseptic preparation of the skin and a sterile technique, beyond a
perfect knowledge of species variability, epidural fat, substance lipophilicity, injectable leaks through
intervertebral spaces, and meningocerebral ligament’s individual anatomy, which may interfere with
the product administration and even cause some adverse effects [68,86].
5.7. Intraperitoneal Administration
Intraperitoneally applied drug forms are supposed to be located in the peritoneal cavity.
Intraperitoneal injection is mostly performed in small species (e.g., rodents) to overcome the challenging
intravenous, subcutaneous, and intramuscular access or difficulties, as well as to administer large
volumes of substances, to give treatment to the peritoneum cavity, and to perform some surgical
procedures [68,83]. Drug pharmacokinetics is similar to that observed after the oral route, due to
prior absorption into the mesenteric vessels, subsequent drainage into the portal vein, and thus being
subjected to hepatic metabolism before reaching systemic circulation. When performed in mammals,
depending on the species, several procedures are adopted to avoid visceral damage by the needles [83]
and by injected drugs [87]. The injected products should be sterile, isotonic, and nonirritating in
order to avoid complications such as ileus, peritonitis, and adhesions. This is one of the most widely
administration routes, especially in rodent models [88,89]. Limitations are the sensitivity of the tissue
to irritating substances and lesser tolerance to solutions of non-physiological pH. This route is not
applied for diabetes treatment (although it is applied for treatment of other pathologies) to larger
mammals or humans, in which intravenous access is easily performed.
5.8. Intranasal, Intratracheal, and Inhalational Administration
In the less commonly used administration routes, intranasal, intratracheal, and inhalational routes,
drugs are delivered through the respiratory system to access surrounding or system targets. Animals
are usually sedated or anesthetized, in order to reduce struggling and sneezing, and small relative
volumes are delivered to reduce the risk of suffocation and death [68]. Intranasal delivery may be
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applied either to local or systemic delivery of nonirritating substances, as nasal mucosa is rich in blood
vessels, there is a rapid absorption of the product and a rapid systemic effect, since it has avoided
the first-pass effect by the liver [68]. Intranasal administration is becoming a common method to
deliver therapeutic drugs to the central nervous system (CNS), as it is non-invasive and allows large
molecules that do not cross the BBB to access the CNS, with reduced systemic exposure and unwanted
systemic side effects [90]. In turn, intrapulmonary delivery may be performed by (1) intratracheal
instillation, an easier but not so effective technique which involves small volumes injected directly
into the trachea, or (2) inhalation, a highly complex technique that typically uses vapors or aerosols of
nebulized particles in solutions which are deposited by gravitational sedimentation, inertial impaction,
or diffusion in small airways; the ones deposited in large airways are then incorporated into the mucus
and expelled by the mucocilliary clearance. It is thus important to evaluate solvent and propellant
effects, since evaporation may lead to particle size changes [68,89]. Among these, intranasal has shown
increased relevance, due to the direct brain connection and to the development of new pharmaceutical
formulations able to enhance penetration through the nasal mucosa [90,91].
6. Conclusions
Diabetes mellitus is a metabolic disorder characterized by several disturbances in carbohydrate,
protein, and fat metabolism and, apart from the need to discover new and more effective anti-diabetic
drugs, animal models cannot be avoided in pre-clinical research. Several animal models are available
according to the type of diabetes and also with the aim of therapy to assess. In this sense, animal models
should be carefully chosen in order to fully reproduce the mechanisms and pharmacokinetics of the
proposed therapies. Moreover, drug administration is of extreme relevance, both in the preclinical and
clinical stages. Especially during preclinical studies, administration route advantages and drawbacks
should be taken into account and the route should be adequate in order to reproduce human pathology
and suitable treatment for further clinical trials.
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